Company intelligence / Profile preview

Vergent Bioscience

Minneapolis, Minnesota, United Statesvergentbio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Currently sponsoring a Phase 2b multi-center study evaluating abenacianine for injection (VGT-309) in surgery for cancer in the lung at leading hospitals in the U.S. and Australia. Recent Phase 2 data showed VGT-309 visualizes tumors in the lung during surgery (as of June 3, 2024)[4].

Therapeutic areas: Oncology
Modalities: Fluorescent imaging agentsTumor-targeted agents
Industry: Biotech

Drug pipeline

1 asset

abenacianine

Partnerships

Intuitive (investor)

Beyond the preview

Go deeper on Vergent Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vergent Bioscience.

Explore the full profile